SUMMER 2023 SYMPOSIUM

Rare Tumors: Ideas for Implementation of Novel Concepts

Thursday, July 20, 2023 - 8 am -12 noon - ET
Philadelphia Marriott, Phila, PA

Program Chair
Allan Covens, MD
Sunnybrook Health Sci Ctr

Program Chair
Jubilee Brown, MD
Atrium Health Levine Cancer Inst

Rebecca Arend, MD
UAB Medicine

Junzo Chino, MD
Duke Cancer Center

Britt Erickson, MD
University of Minnesota

Danielle Enserro, PhD
NRG, Statistics/Data Mgmt Ctr, Buffalo

Amanda Fader, MD
Johns Hopkins Med Ctr

Lilian Gien, MD
Sunnybrook Health Sci Ctr

Rachel Grisham, MD
Memorial Sloan Kettering Can Ctr

R. Tyler Hillman, MD, PhD
UT MD Anderson Can Ctr

Michael Kelly, MD
Wake Forest Baptist Health

Elise C. Kohn, MD
National Cancer Institute

Haider Mahdi, MD
Univ of Pittsburgh Med Ctr

Alexandra Thomas, MD
Wake Forest Baptist Health

Danielle Vicus MD
Sunnybrook Health Sci Ctr

AMA PRA Category 1 Credits™ The GOG Foundation, Inc. designates this live internet activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Agenda on next page
Summer 2023 Symposium Agenda

Rare Tumors: Ideas for Implementation of Novel Concepts

Thursday, July 20, 2023 – 8 am to 12 pm – (ET)

NRG Oncology Summer 2023 Meeting – Philadelphia Marriott – Philadelphia, PA

Program Chairs: Jubilee Brown, MD and Allan Covens, MD

PROGRAM DESCRIPTION:
The Summer 2023 Hybrid Educational Symposium is titled “Rare Tumors: Ideas for Implementation of Novel Concepts” with noted oncologists and scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: gynecologic oncologists, medical oncologists, radiation oncologists, pathologists, patient advocates and others engaged in oncology research and/or clinical practice; oncology nurses, nurse-practitioners, and other interested allied health professionals.

The speakers will focus their presentations on the design, implementation strategies, and progress in clinical trials involving rare tumors. The information presented will span novel clinical trial design with incorporation of novel statistical design and molecular profiling. Experts will share insights on NCI funding and coordination of work with other disease sites. Attendees will learn from faculty with experience in rare gynecologic and breast cancers, incorporating radiation and surgical components, with specific emphasis on trials that have had successful outcomes.

LEARNING OBJECTIVES:
Following this activity, participants will be better able to:

1. Design clinical trials
2. Synthesize components of published clinical trials
3. Implement new strategies in patient care informed by outcomes of clinical trials in rare tumors

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic/Title</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Breakfast Buffet</td>
<td></td>
</tr>
<tr>
<td>8:00 am</td>
<td>Welcome/Opening Remarks</td>
<td>Allan Covens, MD</td>
</tr>
<tr>
<td>8:05 – 10:00 am</td>
<td>Session 1 – Rare Tumor Trials: Progress and Pitfalls</td>
<td>Moderators: Jubilee Brown, MD and Amanda Fader, MD</td>
</tr>
<tr>
<td>8:05 – 8:15</td>
<td>Lessons Learned from NRG trials in Rare Gynecologic Cancers</td>
<td>Jubilee Brown, MD</td>
</tr>
<tr>
<td>8:15 – 8:30</td>
<td>Novel Trial Design and Statistics for Rare Tumor Trials</td>
<td>Danielle Enserro, PhD</td>
</tr>
<tr>
<td>8:30 – 8:45</td>
<td>NCI: Priorities and Funding for Rare Tumor Trials</td>
<td>Elise Kohn, MD</td>
</tr>
<tr>
<td>8:45 – 8:50</td>
<td>Updates in Gynecologic Rare Tumor Trials</td>
<td>Allan Covens, MD</td>
</tr>
<tr>
<td>8:50 – 9:20</td>
<td>Low Grade Serous Ovarian Cancer &amp; Should Rare Tumor Concepts be Evaluated Differently?</td>
<td>Rachel Grisham, MD</td>
</tr>
<tr>
<td>9:20 - 9:35</td>
<td>Stromal Tumors of the Ovary</td>
<td>R. Tyler Hillman, MD, PhD</td>
</tr>
<tr>
<td>9:35 – 9:45</td>
<td>Questions and discussion</td>
<td></td>
</tr>
<tr>
<td>9:45 – 10:00</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>10:00 am – 12:00 pm</td>
<td>Session 2 – Rare Tumor Trial Design – Past the Surface</td>
<td>Moderators: Allan Covens, MD and Haider Mahdi, MD</td>
</tr>
<tr>
<td>10:10 – 10:15</td>
<td>Clear Cell Carcinoma</td>
<td>Lilian Gien, MD</td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Presenter</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>Update in Breast Cancer Rare Tumor Trials</td>
<td>Alexandra Thomas, MD</td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td>How does Molecular Profiling inform Rare Tumor Study?</td>
<td>Rebecca Arend, MD</td>
</tr>
<tr>
<td>10:45 – 11:00</td>
<td>Role of Radiation and Surgery in Rare Tumor Trials - Surgery</td>
<td>Michael Kelly, MD</td>
</tr>
<tr>
<td>11:00 – 11:15</td>
<td>Role of Radiation and Surgery in Rare Tumor Trials - Radiation</td>
<td>Junzo Chino, MD</td>
</tr>
<tr>
<td>11:15 – 11:30</td>
<td>Developing a Program of Study: Her2+ Tumors</td>
<td>Britt Erickson, MD</td>
</tr>
<tr>
<td>11:30 – 11:45</td>
<td>Developing Clinical Trials in previously Non-NRG Diseases and across Multi-tumor Sites</td>
<td>Danielle Vicus, MD</td>
</tr>
</tbody>
</table>

11:45 – 12:00 pm  Questions and discussion

**Continuing Education**

**Accreditation Statement**
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

**AMA PRA Category 1 Credits™**
The GOG Foundation, Inc. designates this live internet activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Evaluation**
Participants who complete the educational activity, evaluation and attendance verification will receive a certificate of credit.

**Disclosure Declaration**
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. All relevant financial relationships listed for these individuals have been mitigated to ensure a bias-free presentation. Please see the faculty disclosure list for detailed information.